BOSTON
and LAUSANNE, Switzerland, Jan.
26, 2022 /PRNewswire/ -- SOPHiA GENETICS SA (Nasdaq:
SOPH), the creator of a global data pooling and knowledge sharing
platform that democratizes data-driven medicine, today
announced that Ken Freedman has been appointed Chief Revenue
Officer. With a background in serving some of the most innovative
providers of technology to the world-wide media space, Ken brings
more than 25 years of sales, marketing, and executive management
experience.
Previously, Ken was the Executive Vice President of Sales for
Naviga where he grew revenue streams, built processes, and helped
customers from Canada to
Latin America find success. Prior
to that, Ken was part of the executive team involved in selling
MediaSpan to Vista Equity Partners during the early days of
Newscycle. Earlier in his career, he led the Go to Market efforts
as EVP managing sales, marketing, technical support, and operations
for FileFlow Technologies.
"I am pleased to welcome Ken to our team. His motivational
leadership style and expertise in Go-to-Market strategy and
execution will be a great addition as we continue our U.S. and
global expansion plans," said Jurgi Camblong, co-founder and CEO of
SOPHiA GENETICS. "Ken is joining us at a very exciting time – fresh
off our successful IPO. His belief in data-driven logic will aid us
in our mission as we enter into another exciting year of
growth."
"I am very excited to meld my expertise in cloud-based platform
processes and sales with the innovative products and team at
SOPHiA. It's a privilege to join a team that is dedicated to
enabling healthcare institutions worldwide in their efforts to
improve patient outcomes, and I look forward to helping grow access
to SOPHiA's products and solutions in my new role," said
Freedman.
Ken graduated from University of
Massachusetts Amherst with a degree in Mass Communications.
He resides in Falmouth, MA with
his wife, two daughters, and English bulldog. He is based in the
company's US headquarters in Boston.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH)
is a healthcare technology company dedicated to establishing the
practice of data-driven medicine as the standard of care and for
life sciences research. It is the creator of the SOPHiA DDM™
Platform, a cloud-based SaaS platform capable of analyzing data and
generating insights from complex multimodal data sets and different
diagnostic modalities. The SOPHiA DDM™ Platform and related
solutions, products and services are currently used by more than
790 hospital, laboratory, and biopharma institutions globally. For
more information, visit SOPHiAGENETICS.COM, or connect on Twitter,
LinkedIn and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information included in this press release is about products that
may or may not be available in different countries and, if
applicable, may or may not have received approval or market
clearance by a governmental regulatory body for different
indications for use. Please contact
support@sophiagenertics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This
press release contains statements that constitute forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding our future results of operations and financial position,
business strategy, products and technology, as well as plans and
objectives of management for future operations, are forward-looking
statements. Forward-looking statements are based on our
management's beliefs and assumptions and on information currently
available to our management. Such statements are subject to risks
and uncertainties, and actual results may differ materially from
those expressed or implied in the forward-looking statements due to
various factors, including those described in our filings with the
U.S. Securities and Exchange Commission. No assurance can be given
that such future results will be achieved. Such forward-looking
statements contained in this document speak only as of the date of
this press release. We expressly disclaim any obligation or
undertaking to update these forward-looking statements contained in
this press release to reflect any change in our expectations or any
change in events, conditions, or circumstances on which such
statements are based, unless required to do so by applicable law.
No representations or warranties (expressed or implied) are made
about the accuracy of any such forward-looking statements.
Logo -
https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg